Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13

 

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
      Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing.